CAR T-cell Therapy for Multiple Myeloma - A Pipeline Analysis Report

Overview of the pipeline analysis report on car T-cell therapy for multiple myeloma

CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma. Our analysts predict that the increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area.

Technavio’s pipeline analysis report on car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.

Key companies

This pipeline analysis report has identified thirteen companies that are actively involved in the development of car T-cell therapy for multiple myeloma. This report has segregated the players into Tier 1, Tier 2, and Tier 3 companies based on their revenue,. One of the Tier 1 companies Juno Therapeutics, is a major player in the biotechnology industry and has registered a revenue of more than USD 79 million in 2016.